New CEO: SEC was warm-up for ACCME

Share this article:
As John Connolly settles into his new post as president & CEO of M|C Communications, he may find certain experiences from his past especially useful.

Compliance is one area. Connolly was formerly president and CEO of Institutional Shareholder Services (ISS), manager of proxy voting and other corporate governance tasks for public companies.

In an interview, the new CEO drew comparisons between Securities and Exchange Commission (SEC) requirements in his previous business and those of the Accreditation Council for Continuing Medical Education in the CME business, saying his “appreciation and skill set” for compliance will serve him well in his new role.

So will being in the spotlight and talking with the media.

“ISS was on CNBC 20 times in the last 24 months while I was there,” Connolly recalled.
He takes over the position from John Mooney, who will remain chairman, the company said. Mooney, having led M|C Communications for 13 years, stepped down to spend more time with his family, including a three-year-old daughter.

M|C Communications produces the Pri-Med Conference & Exhibitions, one of the largest series of educational meetings aimed at primary care physicians. In 2008, the company forecasts over 150,000 US MDs will attend its sessions, 350,000 globally.

Pri-Med already runs a group of smaller conferences and symposia called Updates, as well as med ed programs for psychiatrists, pharmacists, cardiologists and neurologists.

It plans to launch into other markets, including oncology, soon, Connolly said. Its big, live confabs aimed at GPs will also see more interactivity, with programming delivered on digital devices.

In 1989 Connolly started publishing firm Course Technology, which he sold two years later to Thomson and became CEO of Thomson Media.

Before that, he held senior posts with publishers Lippincott Williams and Wilkins and the educational group of Addison-Wesley.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...